SF3B2

Across TCGA pan-cancer cohorts, SF3B2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SF3B2 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SF3B2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SF3B2 expression acts as an unfavorable survival marker.

READ, LUAD, and DLBC are the cancer types where SF3B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.173	0.828	<.001	39	view →
LUAD	OS	Median	II,III,IV	0.141	0.677	.002	15	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.019	9	view →
KIRP	OS	Median	All	0.105	0.688	.004	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SCLC	OS	Median	All	0.405	0.783	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SF3B2–READ (OS)

Open the READ breakdown →